EUVIMEDEUVIMED entdecken
Fallbericht

Ilunocitinib-Induced Pancytopenia in an Australian Shepherd Dog with the MDR1 Mutation

Katrina L Mealey, Mary McFillen, Alisa Hutchison

Journal of the American Animal Hospital Association · 01.05.2026 · 62 (3) · 127-130

DOI: 10.5326/jaaha-ms-7552 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of the American Animal Hospital Association, erschienen am 01.05.2026. Verfasst von Katrina L Mealey und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Dog Diseases, ATP Binding Cassette Transporter, Subfamily B, Member 1, Pancytopenia. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A 5 yr old female spayed Australian shepherd dog with a prior diagnosis of atopy presented for increased pruritus despite immunotherapy. The dog had a history of seizures well controlled by levetiracetam and was genotyped as MDR1 mutant/normal. Ilunocitinib, indicated for controlling pruritus in dogs, was considered. Because the label indicates ilunocitinib can cause cytopenias, a complete blood count (CBC) was performed before initiating treatment. Neutrophils, platelets, and red blood cell numbers were all within reference ranges, so treatment with ilunocitinib was initiated. At a 1 mo follow-up appointment, the dog was bright, alert, and responsive with an improved Pruritus Visual Analog Scale score. A CBC indicated pancytopenia. Ilunocitinib was discontinued and a CBC was repeated after 7 days, indicating resolution of neutropenia and thrombocytopenia, but persisting anemia. One month after discontinuing ilunocitinib, all cytopenias had resolved. Because of the dog’s MDR1 genotype, the status of ilunocitinib as a canine P-glycoprotein substrate was assessed. Ilunocitinib was identified as a canine P-glycoprotein substrate. Blunted P-glycoprotein–mediated biliary excretion of ilunocitinib likely resulted in accumulation and a relative overdose. Enhanced penetration of ilunocitinib into hematopoietic stem cells lacking P-glycoprotein expression may have also contributed to dysregulated hematopoiesis. Ilunocitinib should be used cautiously in dogs with P-glycoprotein deficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dog DiseasesATP Binding Cassette Transporter, Subfamily B, Member 1PancytopeniaAnimalsDogsFemaleMutation

Substanzen

ATP Binding Cassette Transporter, Subfamily B, Member 1

Zitieren

APA

Mealey, K. L., McFillen, M., & Hutchison, A. (2026). Ilunocitinib-Induced Pancytopenia in an Australian Shepherd Dog with the MDR1 Mutation. Journal of the American Animal Hospital Association, 62(3), 127-130. https://doi.org/10.5326/jaaha-ms-7552

Vancouver

Mealey KL, McFillen M, Hutchison A. Ilunocitinib-Induced Pancytopenia in an Australian Shepherd Dog with the MDR1 Mutation. Journal of the American Animal Hospital Association. 2026;62(3):127-130. doi:10.5326/jaaha-ms-7552

BibTeX
@article{Mealey2026,
  author = {Mealey, Katrina L and McFillen, Mary and Hutchison, Alisa},
  title = {Ilunocitinib-Induced Pancytopenia in an Australian Shepherd Dog with the MDR1 Mutation},
  journal = {Journal of the American Animal Hospital Association},
  year = {2026},
  volume = {62},
  number = {3},
  pages = {127--130},
  doi = {10.5326/jaaha-ms-7552}
}
Kostenlos starten →